BEATRICE Trial Evaluating the Addition of Bevacizumab to Adjuvant Chemotherapy for Triple-Negative Breast Cancer


BEATRICE Trial Evaluating the Addition of Bevacizumab to Adjuvant Chemotherapy for Triple-Negative Breast Cancer
Slides from a presentation at SABCS 2012 and transcribed comments from a recent interview with Lisa A Carey, MD (1/17/13)

Cameron D et al. Primary results of BEATRICE, a randomized Phase III trial evaluating adjuvant bevacizumab-containing therapy in triple-negative breast cancer. San Antonio Breast Cancer Symposium 2012;Abstract S6-5.

Dr Carey is Richardson and Marilyn Jacobs Preyer Distinguished Professor for Breast Cancer Research, Chief of the Division of Hematology and Oncology, Physician-in-Chief at the North Carolina Cancer Hospital and Associate Director for Clinical Research at the Lineberger Comprehensive Cancer Center in Chapel Hill, North Carolina.